ADC Therapeutics (ADCT) Scheduled to Post Earnings on Monday

ADC Therapeutics (NYSE:ADCT) will be announcing its earnings results before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.56). The business had revenue of $16.79 million for the quarter, compared to the consensus estimate of $16.58 million. ADC Therapeutics had a negative return on equity of 1,313.37% and a negative net margin of 344.15%. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Up 3.6 %

Shares of ADCT stock opened at $4.90 on Friday. ADC Therapeutics has a 12 month low of $0.36 and a 12 month high of $6.04. The company’s fifty day simple moving average is $4.59 and its 200-day simple moving average is $2.82. The firm has a market cap of $405.77 million, a PE ratio of -1.67 and a beta of 1.69.

Analyst Ratings Changes

Several equities research analysts have commented on ADCT shares. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Thursday, March 14th. Guggenheim reiterated a “buy” rating on shares of ADC Therapeutics in a report on Friday, April 5th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of ADC Therapeutics in a research report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, ADC Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.